NASDAQ$TCMD

Tactile Systems Technology Inc · Q1 2020 earnings

Q1 2020 earnings · · Investor relations

Briefing

Revenue increased but company faced operating and net losses due to increased expenses and COVID-19 impact.

Tactile Systems Technology reported a 16% increase in total revenue for Q1 2020, reaching $43.7 million. However, the company experienced an operating loss of $4.5 million and a net loss of $1.3 million, impacted by the COVID-19 pandemic and increased operating expenses.

  • Total revenue increased by 16% year-over-year to $43.7 million.
  • Flexitouch revenue increased by 13% year-over-year to $38.6 million.
  • The company faced an operating loss of $4.5 million.
  • Net loss was $1.3 million, or ($0.07) per diluted share.

Headline financials

Total Revenue

$43.7M

Previous: $37.6M+16.1%
EPS (adj)

-$0.05

Previous: $0.08-162.5%
Capital Expenditures

-$358K

Previous: -$731K+51.0%
Free Cash Flow

-$1.67M

Previous: $741K-324.7%
Net Income

-$1.31M

Previous: $1.47M-188.8%
Operating Income

-$4.45M

Previous: -$1.8M-147.0%
Gross Profit

$31.1M

Previous: $26.3M+18.3%
Cash & Equivalents

$32.3M

Previous: $23.5M+37.2%
Total Assets

$156M

Previous: $114M+37.0%
Stock-Based Comp

$2.73M

Previous: $2.78M-2.0%

Revenue & EPS history

Tactile Systems · Revenue · Quarterly

$43.7M

Q1 2020+16.1%vs Q1 2019
Beat estimate in 10 of 15 quarters(67%)
ActualEstimate

Revenue by segment

Tactile Systems · $68.3M total across 2 segments · Q2 2023

  • Lymphedema products
    $60M+16.2%
  • Airway clearance products
    $8.34M+4.1%

Forward guidance

The company withdrew its full year 2020 financial outlook due to the rapidly evolving environment and continued uncertainties associated with COVID-19.

Tailwinds

  • Shift to virtual selling and service strategies shows positive early market response.
  • Company is well-capitalized to weather the crisis.
  • Plan to leverage strong balance sheet to continue expanding commercial organization this year.
  • Focus on being well-positioned to return to delivering strong, sustained and profitable growth as the COVID-19 crisis subsides.
  • Confident in the long-term opportunity related to the growing $5+ billion U.S. lymphedema market.

Headwinds

  • COVID-19 pandemic is expected to continue to impact financial and operational results.
  • Healthcare facilities and clinics restricted access, reduced patient consultations, or announced temporary closings.
  • Unable to predict the extent to which the COVID-19 crisis will impact the business over the near term.
  • Withdrew its full year 2020 financial outlook.
  • Uncertainties associated with COVID-19.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q1 2020

Historical avgQ1 2020

+3.1%

Avg return

Earnings day

+3.6%

Avg return

5 days after

+5.9%

Avg return

30 days after

64%

29 / 45 earnings

Positive

+40.6%

Q3 2025

Best reaction

-29.0%

Q1 2025

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+7.2%+14.5%+12.2%
Q4 2025+17.4%+2.2%-7.0%
Q3 2025+40.6%+57.6%+70.0%
Q1 2025-29.0%-31.6%-27.5%
Q4 2024-13.3%-16.6%-25.6%
Q3 2024-8.6%+2.2%+29.5%
Q2 2024+7.2%+8.6%+8.4%
Q1 2024+1.1%-2.6%-15.2%
Q4 2023-5.4%+8.0%+12.6%
Q3 2023-22.8%-16.9%+1.3%
Q2 2023-14.7%-10.2%-10.1%
Q1 2023+14.0%+15.7%+29.6%
Q4 2022+2.4%+7.6%+13.5%
Q3 2022+17.8%+27.5%+49.9%
Q2 2022+18.2%+15.0%+6.5%
Q1 2022+2.4%-22.9%-41.8%
Q4 2021+7.3%+29.9%+30.6%
Q3 2021-22.9%-22.1%-44.1%
Q2 2021-9.1%-10.8%-8.6%
Q1 2021-7.5%-2.4%-9.0%
Q4 2020-10.4%-15.0%-13.7%
Q3 2020+5.4%-2.7%+14.4%
Q2 2020-13.3%-8.4%-9.9%
Q1 2020-1.0%+3.2%+4.8%
Q4 2019-2.8%-6.3%-28.2%
Q3 2019+7.8%+12.4%+35.8%
Q2 2019-9.6%-7.6%-11.3%
Q1 2019+4.5%+4.0%-4.6%
Q4 2018+0.4%+2.9%-27.5%
Q3 2018-7.9%-5.6%-18.2%
Q2 2018+13.4%+12.4%+37.6%
Q1 2018+20.0%+26.8%+41.2%
Q4 2017+7.8%+1.6%-0.8%
Q3 2017-10.4%-7.6%-1.1%
Q2 2017+17.4%+7.7%+19.3%
Q1 2016+13.9%+22.1%+31.1%
Q1 2017+13.9%+22.1%+31.1%
Q1 2015+17.7%+10.2%+6.1%
Q4 2016+17.7%+10.2%+6.1%
Q4 2014+17.7%+10.2%+6.1%
Q3 2015+7.6%+2.1%-11.1%
Q3 2016+7.6%+2.1%-11.1%
Q4 2015+6.8%+3.9%+31.8%
Q2 2016+6.8%+3.9%+31.8%
Q2 2015+6.8%+3.9%+31.8%
Q3 2014
Q2 2014
Q1 2014

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro